BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/24/2023 6:10:12 AM | Browse: 61 | Download: 103
 |
Received |
|
2023-07-08 16:54 |
|
Peer-Review Started |
|
2023-07-08 16:57 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-08-15 18:11 |
|
Revised |
|
2023-09-05 20:01 |
|
Second Decision |
|
2023-10-13 09:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-10-23 02:29 |
|
Articles in Press |
|
2023-10-23 02:29 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-10-24 06:36 |
|
Publish the Manuscript Online |
|
2023-11-24 06:10 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Observational Study |
| Article Title |
Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jessica A Ward, Jason Yerke, Mollie Lumpkin, Aanchal Kapoor, Christina C Lindenmeyer and Stephanie Bass |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jessica A Ward, PharmD, Pharmacist, Department of Pharmacy, Cleveland Clinic, No. 9500 Euclid Avenue, Hb-115, Cleveland, OH 44195, United States. wardj4@ccf.org |
| Key Words |
Rifaximin; Hepatic encephalopathy; Critical illness; Antibiotics; Liver disease; Cirrhosis |
| Core Tip |
Critically ill patients with liver disease receiving broad-spectrum antibiotic therapy have been frequently excluded from clinical trials of rifaximin efficacy. Therefore, despite overlapping spectrums of antibacterial activity, it is not known if rifaximin provides additional clinical benefit in these patients. In this study, pharmacist-guided rifaximin discontinuation during broad-spectrum antibiotic therapy resulted in significant cost savings and was not associated with negative short-term cognitive effects or adverse events. |
| Publish Date |
2023-11-24 06:10 |
| Citation |
Ward JA, Yerke J, Lumpkin M, Kapoor A, Lindenmeyer CC, Bass S. Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy. World J Hepatol 2023; 15(11): 1226-1236 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i11/1226.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i11.1226 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
